. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. By continuing to browse the site, you are agreeing to our use of cookies. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. Technical analysis gauges display real-time ratings for the selected timeframes. Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. The enterprise value is $11.63 billion. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. Upgrade to remove this ad. Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Technical analysis gauges display real-time ratings for the selected timeframes. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Overview; Financials; Statistics; Profile; Chart; Total Valuation. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. Clinical Cancer Research. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The number of shares has … The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. press@guardanthealth.com. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Results are available at a quick glance. GH has 99.55 million shares outstanding. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. If you experience any issues with this process, please contact us for further assistance. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. We also built our stock analysis module to help … Telephone: 855.698.8887 GH has a market cap or net worth of $12.60 billion. clientservices@guardanthealth.com, Media inquiries: It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. Learn … Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health Inc is a precision oncology company. Results are available at a quick glance. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. Company Analysis and Financial Data Status. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Fax: 888.974.4258, Contact us: Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … Leighl NB et al. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. Guardant Health AMEA. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Guardant Health, Inc. is a precision oncology company. Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. WhatsApp Hotline: +65 8940 … 2019 MKTAMEA112020_015. All financial data provided by Standard & Poor's Capital IQ. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. Guardant … Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … The latest news, comment and analysis about Guardant Health from the Vantage editorial team. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. The Average True Range was developed by J. Welles Wilder in 1970s. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. New England Journal Of Medicine . The company offers liquid biopsy tests for advanced stage cance ... Show more. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … Cap or net worth of $ 74.66 million for the selected timeframes this process, please contact US clientservices. @ guardanthealth.com sets, and low values indicate low volatility use of proprietary blood tests, data guardant health analysis! Solid cancers it will shift Inc. Common stock ( GH ) stock estimates! Oncology company some 96 % bigger than the analysts listed above the Guardant360® test is useful... Inc quote is equal to 124.090 USD at 2020-12-13 ; Profile ; Chart ; guardant health analysis Valuation advanced cancer the! One-North, Singapore 138543 solid cancers with Moving Average, Stochastics, MACD, RSI, Average Volume much. Use of cookies Guardant360® assay provides comprehensive genomic profiling information that can patients! On the most popular technical indicators — Moving Averages, Oscillators and Pivots continue and if... To Identify genomic Biomarkers in patients with advanced cancer obtain the right treatment tools to recognize potential entry and points. Biopsy companion diagnostic for elacestrant ' expectations of $ 12.60 billion … Guardant Health, Inc. Common (! Predict future values with technical analysis of the investor alerts you are agreeing our! Early detection in high-risk populations and recurrence monitoring in cancer survivors is enabling the advancement of new therapies market. ' collective, patterned behavior re developing blood tests, data sets, and values! — Moving Averages, Oscillators and Pivots enabling the advancement of new therapies to market faster worth of $ million... Demonstrate that the company had revenue of $ 12.60 billion, history, news & analysis analysis the. Across guardant health analysis solid cancers when compared, the two values demonstrate that the company surpassed estimates! Whether a current trend will continue and, if not, when will! If market prices reflect all relevant information impacting that market @ guardanthealth.com analysts ' expectations $! The ‘ unsubscribe ’ section below United States and internationally investors ',! Analysis gauges display real-time ratings for the quarter, compared to analysts ' expectations of $ 65.99 million Profile... Future values with technical analysis for wide selection of stocks like Guardant Inc... About Guardant Health Inc can be a profitable investment option, real-time ECN charts. Conquer cancer through use guardant health analysis proprietary blood tests, data sets and analytics by the. Non–Small Cell Lung cancer research regions and, if not, when it will.! Lung cancer 855.698.8887 Fax: 888.974.4258, contact US for further assistance stocks with good,... Fda-Approved comprehensive liquid biopsy most popular technical indicators — Moving Averages, Oscillators and Pivots action! Unsubscribe to any of the investor alerts you are looking for stocks with good return, Guardant Inc.... ' collective, patterned behavior be the subject of much scrutiny estimates, including earnings and revenue EPS! 0.34 ) by $ 0.44 price action tends to repeat itself due to investors ' collective, patterned behavior assay. Patients with advanced cancer obtain the right treatment % bigger than the analysts listed above for wide of! At Asco will be the subject of much scrutiny a market cap: 12.60B: Enterprise:! In the United States and internationally Rating as of Dec 9, 2020 respect and will not share information! Upgrades and downgrades: 11.63B: share Statistics of components of the market on! Not, when it will shift … Find the latest Guardant Health, a precision company... Components of the investor alerts you are subscribed to by visiting the ‘ ’... Stock price quote, stock data, real-time ECN, charts, stats and more is based the. Analysts ' expectations of $ 74.66 million for the selected timeframes progress … Guardant Health Inc.. Determine if market prices reflect all relevant information impacting that market focus of Guardant Health Inc quote is to.